DeCure's autonomous Cancer AI scientist is researching a drug-repurposing hypothesis for oral squamous cell carcinoma — screening already-approved drugs against its 49-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleOral squamous cell carcinoma maps to a 49-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for oral squamous cell carcinoma is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
fibroblast growth factor receptor 4 (FGFR4) — FGFR4 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 1~{r}drag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 8KH8 · 1.49 Å · ligand 1-[4-[(1~{R})-1-[3,5-bis(chloranyl)pyridin-4-yl]ethoxy]-5-cyano-pyridin-2-yl]-3-[6-methanoyl-5-[(4-methyl-2-oxidanylidene-piperazin-1-yl)methyl]-3-(2-morpholin-4-ylethoxy)pyridin-2-yl]urea (VVW). Experimental structure, not a prediction.
What the evidence adds up to
Oral squamous cell carcinoma is the most common malignant epithelial neoplasm of the oral cavity, and surgery remains the cornerstone of curative treatment, either alone or combined with radiotherapy. For recurrent or metastatic disease that is not suitable for curative surgery, non-surgical options include radiotherapy, chemotherapy, molecular targeted agents, and immunotherapy, used alone or in combination. A 2022 review of these approaches states that all factors must be considered within a multidisciplinary team, but provides no new trial data or survival figures. A 2003 review notes the prognosis is relatively poor and that treatment affects speech, swallowing, and mastication.
A 2021 systematic review of therapeutic options in unresectable oral squamous cell carcinoma identified 33 studies, most observational, with sample sizes from 16 to 916 participants. The review concludes there is lacking evidence about the benefits of some therapeutic options for unresectable disease. It states that patients can be treated with a multimodal approach such as concurrent chemoradiotherapy or induction chemotherapy followed by chemoradiotherapy, which have shown good clinical outcomes, but that other options should be considered based on risk/benefit, tumour extension, and patient preferences. No specific response rates or survival data from individual studies are reported in the review.
Two case reports from 2021 and 2024 describe individual patients but provide no generalisable efficacy data. One emphasises the diagnostic dilemma and management protocols of OSCC; the other describes a patient who initially refused surgery due to the extent of resection required but was later satisfied with the outcome. Neither reports survival or tumour response.
What is still missing are large, randomised controlled trials that directly compare treatment sequences in unresectable or recurrent/metastatic oral squamous cell carcinoma. The evidence base remains dominated by observational studies with variable quality, and no single regimen has been established as superior in a definitive trial. Patient stratification by biomarker status or tumour biology is not yet standard, and funding for adequately powered head-to-head comparisons is lacking.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Diagnostics · 2022 · 30 citations · open access
Radiotherapy, Chemotherapy and Immunotherapy—Current Practice and Future Perspectives for Recurrent/Metastatic Oral Cavity Squamous Cell Carcinoma
AbstractOral squamous cell carcinoma is the most common malignant epithelial neoplasm affecting the oral cavity. While surgical resection is the cornerstone of a multimodal curative approach, some tumors are deemed recurrent or metastatic (R/M) and often not suitable for curative surgery. This mainly occurs due to the extent of lesions or when surgery is expected to result in poor functional outcomes. Amongst the main non-surgical therapeutic options for oral squamous cell carcinoma are radiotherapy, chemotherapy, molecular targeted agents, and immunotherapy. Depending on the disease setting, these therapeutic approaches can be used isolated or in combination, with distinct efficacy and side effects. All these factors must be considered for treatment decisions within a multidisciplinary approach. The present article reviews the evidence regarding the treatment of patients with R/M oral squamous cell carcinoma. The main goal is to provide an overview of available treatment options and address future therapeutic perspectives.
Cancer Management and Research · 2021 · 18 citations · open access
Therapeutic Options in Unresectable Oral Squamous Cell Carcinoma: A Systematic Review
AbstractPURPOSE: This review describes the current scientific evidence of therapeutic options in unresectable oral squamous cell carcinoma. METHODS: This study followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). We searched MEDLINE (Via PubMed) to identify studies assessing treatments for unresectable oral squamous cell carcinoma. The methodological quality assessment of the included studies was performed using the Joanna Briggs Institute (JBI) checklist tool. The evidence was organized and presented using tables and narrative synthesis. RESULTS: Thirty-three studies met the eligibility criteria. Most studies had an observational design. The sample size varied from 16 to 916 participants. The methodology quality of the included studies ranged from 2.5 to 10 using the JBI tool. Overall, the optimal treatment of patients with unresectable oral cancer is challenging, so there is a sprinkling of studies assessing a variety of therapeutic options, such as radiotherapy, chemotherapy, concurrent chemoradiotherapy, immunotherapy, targeted therapy plus chemotherapy or radiotherapy, and gene therapy plus chemotherapy. CONCLUSION: There is lacking evidence about the benefits of some therapeutic options for unresectable oral squamous cell carcinoma. Overall, these patients can be treated using a multimodal approach such as concurrent chemoradiotherapy or induction chemotherapy followed by chemoradiotherapy, which have shown good clinical outcomes. However, other options could be considered depending on the assessment of risk/benefits, tumor extension, and patient values and preferences.
AbstractSquamous cell carcinoma is the most common oral malignancy, with a relatively poor prognosis. Treatment of oral cancer has a major impact on afflicted patients because it affects speech, swallowing and mastication. Surgery is the main treatment of oral cancer, as a single modality or combined with radiotherapy. Vigilance is vital for early diagnosis and better overall prognosis.
Gaceta Mexicana de Oncología · 2024 · 0 citations · open access
Squamous cell carcinoma in the malar region. Case report
AbstractSquamous cell carcinoma is the most frequent malignant tumor originating in the mucosa of the oral cavity and oropharynx.In initial stages, the therapeutic approach is surgical.The following case was approached by a multidisciplinary team offering a stepped treatment and thus, balancing oncological safety, functionality and quality of life.Male with prolonged sun exposure, dermatosis located at the right palpebral commissure with 3 years of evolution until presenting evident tumor, initially rejected the surgical proposal due to the need for extensive resection; however, he is currently satisfied with the results surpassing his expectations.
International Journal of Maxillofacial Imaging · 2021 · 0 citations · open access
The diagnostic dilemma of the most common malignancy in orofacial region involving maxillary tuberocity: A case report
AbstractOral squamous cell carcinoma (OSCC) is the most common malignancy affecting the oral cavity. OSCC presents diverse clinical features including small ulcerative lesion to a large growth. The treatment modality of OSCC depends upon the severity, progress and spread of the disease. The purpose of this case report is to emphasize the etiological factors, clinical features as well as the management protocols of OSCC.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
